Kidney transplantation is the treatment of choice for most patients with end-stage renal disease (ESRD) \[[@cit0001], [@cit0002]\]. As patients with kidney disease often have significant comorbidities \[[@cit0003]\], the evaluation of a potential kidney transplant recipient should be as efficient and cost-effective as possible. The initial evaluation of the potential recipient should include a thorough medical, surgical, and psychosocial history and a detailed physical examination to identify comorbidities that could affect candidate survival after the transplantation. It should be stressed that a patient put on the waiting list for transplantation all the time is suffering from the same disease, and after waiting for the transplantation for several years it is not the same as it was at the moment of evaluation.

The aim of this study was to examine demographic and comorbidity factors of patients with end-stage renal disease on the kidney transplantation waiting list in regard to their status (active vs. temporarily disqualified).

The study was conducted on 300 potential kidney transplant recipients (40% females) from 26 dialysis centers in Poland representing 9.7% of all dialyzed patients in these units. Enlisted patients were aged 49 ±13 (35% were \< 50 years). Prevalence of hepatitis B (1.5%) and C (3%) was very low. The cause of end-stage renal failure was hypertensive nephropathy in 29%, chronic glomerulonephritis in 29% and diabetic nephropathy in 25%. Data analyzed were based on the clinical and laboratory parameters in the registration form for kidney transplantation.

Basal clinical and biochemical characteristics of the patients in the active and inactive group are presented in [Table I](#t0001){ref-type="table"} Blood types B and AB were more common in patients on the active list compared to the inactive list (28% vs. 13%, *p* \< 0.05 and 5% vs. 1%, *p* \< 0.05, respectively). Causes of end-stage kidney disease and prevalence of the most common comorbidities, i.e. coronary heart disease, chronic heart failure, hypertension and diabetes, were similar between the two studied groups. Similarly, hepatitis B and C were more prevalent in patients on the inactive list compared to the active list (3.0% vs. 1.5%, *p* \< 0.05, for both). Moreover, hypotensive drug treatment was used in a similar proportion in both groups, with calcium channel blockers being the most prevalent. Statin and acetylsalicylic acid were used in similar proportion in both groups (50% for statins and 48--49% for acetylsalicylic acid). Phosphate binders, cinacalcet and native vitamin D, intravenous iron preparations and erythropoietin stimulating agents were used similarly in regard to frequency and doses. Vascular access modalities were also distributed similarly, with fistula being the most common and graft the least. Inactive status was due to several reasons: invalid (outdated) specialized consultations (70%), treatment of hepatitis (5%), intercurrent illness (9%), recent cardiovascular disease (i.e. recent acute coronary syndrome with dual antiplatelet therapy) (6%), recently diagnosed malignancy or additional diagnostic procedures (10%).

###### 

Clinical and biochemical data of patients on the active and nonactive waiting list

  -------------------------------------------------------------------------------------------------------
  Parameter                            Active list (*n* = 235)   Nonactive list (*n* = 65)
  ------------------------------------ ------------------------- ----------------------------------------
  Age \[years\]                        50.62 ±20.64              49.31 ±14.76

  BMI \[kg/m^2^\]                      25.92 ±4.99               25.64 ±4.36

  Residual diuresis \[ml\]             524 (0; 1100)             562 (0; 100)

  Dialysis vintage \[months\]          27 (1; 168)               35 (1; 189)[\*](#tf1-1){ref-type="fn"}

  Hemoglobin \[g/dl\]                  12.63 ±1.01               10.99 ±1.11[\*](#tf1-1){ref-type="fn"}

  Erythrocyte count \[× 10^12^/µl\]    4.74 ±1.07                4.39 ±0.93

  Leukocyte count\                     7.49 ±1.05                6.38 ±1.75
  \[× 10^6^/µl\]                                                 

  Platelet count\                      214.02 ±108.06            197.74 ±56.82
  \[× 10^12^/µl\]                                                

  AspAT \[IU/l\]                       17.58 ±13.41              19.27 ±14.92

  AlAT \[IU/l\]                        17.23 ±9.48               18.41 ±12.95

  Glucose \[mg/dl\]                    101.80 ±28.44             102.81 ±27.00

  Cholesterol \[mg/dl\]                179.36 ±63.13             181.40 ±57.98

  LDL \[mg/dl\]                        152.62 ±60.09             164.74 ±61.64

  Systolic blood pressure \[mm Hg\]    128.11 ±18.37             132.74 ±15.49

  Diastolic blood pressure \[mm Hg\]   75.95 ±9.27               78.06 ±7.51

  EF (%)                               57.32 ±15.15              59.14 ±13.51

  LVdd \[mm\]                          42.97 ±11.48              52.03 ±12.91

  IVS \[mm\]                           14.16 ±3.51               15.27 ±5.61

  PTH \[pg/ml\]                        496.98 ±394.26            525.66 ±392.16

  Creatinine \[mg/dl\]                 10.20 ±1.55               7.08 ±2.04[\*](#tf1-1){ref-type="fn"}

  eGFR by MDRD \[ml/min/1.72 m^2^\]    8.10 ±3.60                8.43 ±3.12

  Calcium \[mEq/l\]                    4.34 ±0.31                5.14 ±0.33

  Iron \[µg/dl\]                       78.26 ±28.01              80.56 ±37.93

  TSAT (%)                             35.06 ±13.17              36.15 ±15.47

  Ferritin \[µg/l\]                    606.70 ±551.52            664.28 ±602.20
  -------------------------------------------------------------------------------------------------------

P \< 0.05 active vs. nonactive list.

We report the clinical characteristics of the potential kidney transplant recipients on the waiting list in Poland in regard to their status (active vs. nonactive). This is a real world scenario and also a representative sample size. According to healthcare payer requirements, should be not less than 7% of wait-listed and qualified patients in the dialysis center. Patients on the waiting list represent in general less than 10% of the population dialyzed. Inactive status is executed when an intercurrent condition develops that makes transplantation temporarily inadvisable, such as a treatable malignancy or infection. In Europe there are scarce published data on potential kidney allograft recipients in this regard. The percentage of wait-listed patients varied widely, ranging from 27% in the USA to 53% in the UK \[[@cit0004], [@cit0005]\]; however, the precise methods of estimation are not given. Beuscart *et al.* \[[@cit0006]\] identified 7138 patients starting HD as the first renal replacement therapy between January 1, 2002, and December 31, 2006. A total of 176 (2.5%) patients were already wait-listed at the time of HD initiation, and 1392 (19.5%) patients were wait-listed at the cut-off date, but the annual rate and/or prevalence at the certain time point (i.e. the end of the calendar year) were not provided. In another French study \[[@cit0007]\], on 8447 adult patients, aged 18--80 years, who lived and started dialysis in the 11 study regions during the inclusion period (2006--2008), 2498 (29.6%) patients had been placed on the renal transplant waiting list by the end of 2012. The authors provided data on regional variations in the number of donors providing at least one organ, in the number of patients added to the waiting list, and in the number of kidney transplant recipients, but as above no prevalence of wait-listed patients was given. The same applies for USA data; in the OPTN/SRTR (Organ Procurement and Transplantation Network/Scientific Registry for Transplant Recipients) the number of wait-listed patients is given \[[@cit0008]\], while in the USRDS (United States Renal Data System) the number of kidney transplant recipients is given \[[@cit0009]\]; thus the rough estimate of the percentage of wait-listed patients is below 20. In the USA in 2013, the most common reasons for inactive status among newly registered patients included incomplete work-up (74%), too sick (8%), insurance issues (7%), weight inappropriate for transplant (5%), too well (2% to 3%), and candidate choice (1% to 2%) \[[@cit0008]\]. Our data are in agreement only in regard to incomplete work-up. Most adult CKD patients who are being evaluated for transplantation undergo some form of cardiovascular screening at the time of initial evaluation and periodically during the wait-list period. However, it is not clear whether screening asymptomatic patients prior to transplantation provides any benefit or which method of screening is optimal \[[@cit0010]\]. The prevalence of diabetes in the USA is two-fold higher than in Poland. Diabetes is the major cause of ESRD, but also bears a risk of other complications, including cardiovascular ones \[[@cit0011]\]. Several guidelines have been published on the evaluation of potential kidney transplant recipients \[[@cit0012], [@cit0013]\]. In 2014 two guidelines, at least partly relevant to the cardiac evaluation of potential kidney transplant recipients, were published \[[@cit0014], [@cit0015]\]. The major breakthrough is in the part devoted to surgery in patients on dual antiplatelet therapy. From the clinical perspective, in a case of urgency for transplantation, i.e. lack of vascular access, patients do not need to be kept inactive on the waiting list due to dual antiplatelet therapy \[[@cit0015]\]. In addition, some patients, in particular with diabetes, may require either percutaneous coronary intervention (PCI) or cardiac artery bypass grafting (CABG). Thus as reviewed previously, cardiovascular evaluation of potential kidney allograft recipients is of utmost importance \[[@cit0016]\]. A meta-analysis suggested that the strategy of CABG is better than PCI with DES for diabetic patients with multivessel CAD \[[@cit0017]\].

Our patients have shorter dialysis vintage than in the USA, where in 2013, nearly 30% of candidates on the waiting list had been on dialysis for more than 6 years; approximately 10% had been on dialysis \> 11 years \[[@cit0008]\]. In our population the median time to transplant for new candidates was 3 years, while in the USA it was more than 4.5 years for candidates listed in 2009 (indicating the number of days by which 50% of these patients have been transplanted) \[[@cit0008]\].

It should be stressed that prevalence of hepatitis B and/or C in Poland is very low, similar to that in the general population in the world \[[@cit0018]\] as well as in Europe \[[@cit0019]\]. The prevalence of HCV is known to be higher in HD patients (CKD stage 5D) than in the general population, although there is heterogeneity of prevalence depending on the dialysis unit studied and associated with increased mortality \[[@cit0020]\]. According to our study, the temporal suspension on the waiting list is mainly due to the lack of required consultations or outdated consultations in the vast majority of patients. Upon input of the necessary data, patients are wait-listed again. A minority could be temporarily disqualified due to recent malignancy or other recent serious illness. Our study is comprehensive for wait-listed patients and representative for the dialyzed population in Poland. With the expansion of the donor pool including living related donors or even altruistic donors, our waiting list could be even shorter. We should emphasize the need for timely preparation of all necessary diagnostic procedures, laboratory examinations, and consultations for better care of our potential kidney transplant recipients and give them a chance for kidney transplantation in the shortest possible time in the best clinical condition.

In conclusion, kidney transplantation is available only to a minority of the dialyzed population mainly due to significant comorbidities. Inactive status is temporary and mainly due to lack of required consultations. Our data indicate the scale of the task ahead of nephrologists to increase the number of potential kidney transplant recipients, offering them the best possible form of renal replacement therapy.
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